The intravenous immunoglobulin (IVIG) application in renal transplantation is divided into two aspects, immunoregulation of inflammation and immune replacement therapy. The former is mainly used for the desensitization therapy, treatment of antibody-mediated rejection and treatment of steroid-resistant rejection, and the latter is mainly used for the prevention and treatment of hypogammaglobulinemia and infectious complications after renal transplantation. IVIG not only can prevent infection through sterile immunity, but can effectively regulate immune function as well. IVIG is bound to play an increasingly important role in the improvement of prognosis of clinical renal transplantation as its unique feature.